Next Article in Journal
Display of Porcine Epidemic Diarrhea Virus Spike Protein on Baculovirus to Improve Immunogenicity and Protective Efficacy
Next Article in Special Issue
Resistance Development to Bacteriophages Occurring during Bacteriophage Therapy
Previous Article in Journal
Metabolomic Changes in Sogatella furcifera under Southern rice black-streaked dwarf virus Infection and Temperature Stress
Previous Article in Special Issue
The Diversity of Bacterial Lifestyles Hampers Bacteriophage Tenacity
Article Menu
Issue 7 (July) cover image

Export Article

Open AccessReview
Viruses 2018, 10(7), 345; https://doi.org/10.3390/v10070345

Delivering Phage Products to Combat Antibiotic Resistance in Developing Countries: Lessons Learned from the HIV/AIDS Epidemic in Africa

Phages for Global Health, 383 62nd Street, Oakland, CA 94618, USA
Received: 30 May 2018 / Revised: 24 June 2018 / Accepted: 26 June 2018 / Published: 27 June 2018
(This article belongs to the Special Issue Hurdles for Phage Therapy (PT) to Become a Reality)
View Full-Text   |   Download PDF [528 KB, uploaded 27 June 2018]   |  

Abstract

The antimicrobial resistance (AMR) crisis and HIV/AIDS epidemic exhibit many parallels. In both, infectious diseases have caused millions of deaths worldwide, with AMR expected to kill even more people each year than HIV/AIDS did at its peak. In addition, both have required or will require new classes of drugs for control. For HIV/AIDS, development of vital antiretroviral drugs (ARVs) was accomplished in several stages: expanding public awareness about the disease, gathering commitment from the international community to tackle the problem, and eventually establishing policies and global funds to deliver new therapeutics. For AMR, the pursuit of new antimicrobials appears to be following a similar trajectory. This paper examines how lessons and processes leading to ARVs might be applied to developing AMR drugs, in particular bacteriophages (phages). These possess many essential characteristics: inexpensive manufacture, rapid drug development, and a ready means to prevent phage-resistant microbes from emerging. However, the broad application of phage-based products has yet to be fully demonstrated, and will require both international coordination and modified regulatory policies. View Full-Text
Keywords: bacteriophage; phage therapy; antimicrobial resistance; antibiotic; global health; developing countries; infectious disease bacteriophage; phage therapy; antimicrobial resistance; antibiotic; global health; developing countries; infectious disease
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nagel, T.E. Delivering Phage Products to Combat Antibiotic Resistance in Developing Countries: Lessons Learned from the HIV/AIDS Epidemic in Africa. Viruses 2018, 10, 345.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top